Clinical trials: Glial Tumors
Recurrent Glioblastoma
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing…
- Trial name
- NCT04417088
- Testing
- Carboplatin, Exablate BBBD
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- InSightec
Glioma
MRI Contrast Clearance Analysis for Glioma Grading and Genotyping
Gliomas are the most common primary brain tumor. Gliomas with different grades have different clinical behaviors that determine treatment planning and patient prognosis in clinical practice.
- Trial name
- NCT06018870
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Glioma Glioblastoma Multiforme
Functional and Ultrasound Guided Resection of Glioblastoma
Functional and ultrasound-guided resection of glioblastoma: assessing the use of additional imaging during surgery to improve outcomes for patients with glioblastoma brain tumours
- Trial name
- FUTURE-GB (NCT05399524)
- Testing
- Standard of Care, Additional pre- and intra-operative imaging
- Where
- 24 sites in United Kingdom
- Volunteers
- 357 people
- Sponsor
- University of Oxford
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
This pilot phase II trial is studying the side effects and best dose of erlotinib when given with temozolomide and radiation therapy and to see how well they work in treating patients with glioblastoma multiforme or other brain…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00039494
- Testing
- erlotinib hydrochloride, 3-dimensional conformal radiation therapy, temozolomide
- Where
- 139 sites in United States
- Volunteers
- 171 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Childhood Ependymoma
Everolimus for Children With Recurrent or Progressive Ependymoma
The purpose of this study is to evaluate the anti-tumor activity of Everolimus among children with recurrent or progressive ependymoma. Recurrent or progressive ependymoma is incurable and has very limited treatment options.
- Trial name
- NCT02155920
- Testing
- Everolimus
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Texas Southwestern Medical Center
Recurrent Glioblastoma, Glioblastoma - Category
Role of Repeat Resection in Recurrent Glioblastoma
Patients with recurrent Glioblastoma (GBM) are commonly presented to surgeons, along with the question of whether or not to re-resect the recurrence.
- Trial name
- NCT04838782
- Testing
- Repeat Surgical Management of Recurrent GBM
- Where
- Canada
- Sponsor
- University of Alberta
Glioblastoma, Gliosarcoma
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Background: Glioblastoma (GBM) is a type of malignant glioma. These cancers are nearly always fatal. People who develop these cancers get aggressive treatments. But the tumors almost always recur.
- Conditions
- Glioblastoma, Gliosarcoma, Malignant Glioma
- Trial name
- NCT04817254
- Testing
- TMZ, ipilimumab 3mg/kg, Nivolumab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Intrinsic Pontine Glioma
Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines
The purpose of this study is to asses safety of diffuse intrinsic pontine glioma (DIPG) treatment with autologous dendritic cells pulsed with lysated allegenic tumor lines Evaluate the nonspecific immune response generated in…
- Trial name
- NCT02840123
- Testing
- Autologous dendritic cells
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Fundació Sant Joan de Déu
Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
To determine the safety and tolerability of the maximum dose for laboratory engineered Herpes Simplex Virus-1 in patients who would not be eligible for surgical resection of recurrent glioma To determine the safety and…
- Conditions
- Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma or Gliosarcoma
- Trial name
- M032-HSV-1 (NCT02062827)
- Testing
- M032 (NSC 733972)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Alabama at Birmingham
Recurrent Glioblastoma
LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas
This study aims to investigate the safety and efficacy of Laser Interstitial Thermal Therapy (LITT) combined with postoperative early use of temozolomide in treating recurrent glioblastomas.
- Trial name
- NCT05663125
- Testing
- Laser interstitial thermal therapy, Temozolomide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Tiantan Hospital
Medulloblastoma
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
Participants enrolling on this study will receive standard of care chemotherapy for Wnt positive medulloblastoma without the radiation therapy or the weekly chemotherapy that is given during radiation therapy.
- Trial name
- NCT02212574
- Testing
- Lomustine, Vincristine, Cisplatin
- Where
- 16 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma
Evaluating Tumor Pseudoprogression With FLT-PET and MRI
A standard treatment for glioblastoma is a combination of radiation and the drug temozolomide. This combination sometimes causing swelling (inflammation) of the brain tissue.
- Trial name
- NCT01105988
- Testing
- Radiologic exams
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
Brain and Central Nervous System Tumors
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of glioblastoma multiforme.
- Trial name
- NCT00016991
- Testing
- gefitinib
- Where
- United States
- Sponsor
- Duke University
Advanced Malignancies That Harbor IDHR132 Mutations
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
- Trial name
- NCT02381886
- Testing
- IDH305
- Where
- 16 sites in United States, Australia and 6 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Brain Tumor, Recurrent, Glioblastoma
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
The purpose of this study is to test the effectiveness of a drug called temsirolimus in combination with a drug called perifosine in treating brain tumors that have continued to grow after previous treatment.
- Conditions
- Brain Tumor, Recurrent, Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT02238496
- Testing
- Cytoreductive surgery, Perifosine, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Andrew B Lassman, MD
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma
- Trial name
- NCT00049023
- Testing
- 90Y-DOTA-tyr3-OCTREOTIDE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- O'Dorisio, M S
Glioblastoma, Malignant Solid Neoplasm
Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues
This study examines tumor tissues and blood samples to aid in the development of therapies for brain cancer and other solid tumors.
- Trial name
- NCT04822688
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Thomas Jefferson University
Hepatocellular Carcinoma, Glioblastoma
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
- Conditions
- Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer
- Trial name
- NCT04270461
- Testing
- NKG2D-based CAR T-cells
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Jiujiang University Affiliated Hospital
Recurrent Glioblastoma
Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment
Subjects with recurrent glioblastoma who are candidates for bevacizumab treatment according to standard of care will be eligible for this study.
- Trial name
- NCT03573986
- Testing
- [18F]fluoromisonidazole, Bevacizumab, positron emission tomography (PET/CT).
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00014170
- Testing
- gefitinib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.